Holders — by stockHoldings — by fund
Cormorant Asset Management, LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001583977
$1.95B
disclosed book value
50
positions
11%
largest position share
Positions, as of 2026-06-30
top 50 of 50 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PRAXPRAXIS PRECISION MEDICINES I | 640,000 | $214.3M | 11% |
| 2 | BBOTBRIDGEBIO ONCOLOGY THERAPEUT | 17.9M | $136.2M | 7% |
| 3 | PBLSPARABILIS MEDICINES INC | 4.6M | $126.3M | 6.5% |
| 4 | RAPPRAPPORT THERAPEUTICS INC | 2.7M | $110.7M | 5.7% |
| 5 | ERASERASCA INC | 6.0M | $109.9M | 5.6% |
| 6 | EWTXEDGEWISE THERAPEUTICS INC | 2.5M | $102.0M | 5.2% |
| 7 | EYPTEYEPOINT INC | 7.0M | $100.1M | 5.1% |
| 8 | ALMSALUMIS INC | 3.3M | $92.5M | 4.7% |
| 9 | ABVXABIVAX SA | 675,000 | $90.0M | 4.6% |
| 10 | DNTHDIANTHUS THERAPEUTICS INC | 750,000 | $73.1M | 3.7% |
| 11 | DRUGBRIGHT MINDS BIOSCIENCES INC | 900,000 | $63.2M | 3.2% |
| 12 | MLTXMOONLAKE IMMUNOTHERAPEUTICS | 3.2M | $62.4M | 3.2% |
| 13 | BIOABIOAGE LABS INC | 2.4M | $58.6M | 3% |
| 14 | ORKAORUKA THERAPEUTICS INC | 533,340 | $50.8M | 2.6% |
| 15 | ANLADLAI NORTYE LTD | 4.0M | $45.7M | 2.3% |
| 16 | BBIOBRIDGEBIO PHARMA INC | 550,000 | $41.0M | 2.1% |
| 17 | TNGXTANGO THERAPEUTICS INC | 1.3M | $40.6M | 2.1% |
| 18 | BIOHAVEN LTD | 2.6M | $38.8M | 2% |
| 19 | AGMBAGOMAB THERAPEUTICS NV | 2.5M | $32.0M | 1.6% |
| 20 | MBXMBX BIOSCIENCES INC | 550,000 | $30.4M | 1.6% |
| 21 | CLYMCLIMB BIO INC | 2.1M | $27.5M | 1.4% |
| 22 | OLMAOLEMA PHARMACEUTICALS INC | 2.1M | $26.9M | 1.4% |
| 23 | DAMORA THERAPEUTICS INC | 1.0M | $26.0M | 1.3% |
| 24 | PHARVARIS N V | 750,000 | $25.9M | 1.3% |
| 25 | CRBPCORBUS PHARMACEUTICALS HLDGS | 2.3M | $22.0M | 1.1% |
| 26 | SYRESPYRE THERAPEUTICS INC | 225,000 | $20.0M | 1% |
| 27 | DFTXDEFINIUM THERAPEUTICS INC | 400,000 | $18.8M | 1% |
| 28 | NEWAMSTERDAM PHARMA COMPANY | 500,000 | $16.9M | 0.9% |
| 29 | ROIVANT SCIENCES LTD | 475,000 | $16.8M | 0.9% |
| 30 | CABACABALETTA BIO INC | 5.0M | $15.6M | 0.8% |
| 31 | HELIX ACQUISITION CORP III | 1.3M | $13.8M | 0.7% |
| 32 | ASCENDIS PHARMA A/S | 50,000 | $13.3M | 0.7% |
| 33 | KLRAKAILERA THERAPEUTICS INC | 550,000 | $12.1M | 0.6% |
| 34 | INSMINSMED INC | 75,000 | $8.0M | 0.4% |
| 35 | FTHFAETH THERAPEUTICS INC | 1.0M | $7.7M | 0.4% |
| 36 | ELVNENLIVEN THERAPEUTICS INC | 150,000 | $7.6M | 0.4% |
| 37 | TARSTARSUS PHARMACEUTICALS INC | 100,000 | $6.3M | 0.3% |
| 38 | IBIOIBIO INC | 3.6M | $6.2M | 0.3% |
| 39 | CRNXCRINETICS PHARMACEUTICALS IN | 125,000 | $4.7M | 0.2% |
| 40 | ARQTARCUTIS BIOTHERAPEUTICS INC | 175,000 | $4.6M | 0.2% |
| 41 | ARWRARROWHEAD PHARMACEUTICALS IN | 50,000 | $4.1M | 0.2% |
| 42 | GPCRSTRUCTURE THERAPEUTICS INC | 75,000 | $4.0M | 0.2% |
| 43 | RESEARCH ALLIANCE CORP III | 370,000 | $4.0M | 0.2% |
| 44 | COGTCOGENT BIOSCIENCES INC | 100,000 | $3.9M | 0.2% |
| 45 | ALTALTIMMUNE INC | 1.3M | $3.8M | 0.2% |
| 46 | AMLXAMYLYX PHARMACEUTICALS INC | 200,000 | $3.6M | 0.2% |
| 47 | ODTXODYSSEY THERAPEUTICS INC | 175,000 | $3.3M | 0.2% |
| 48 | PCVXVAXCYTE INC | 50,000 | $2.9M | 0.1% |
| 49 | BOLDBOUNDLESS BIO INC | 1.0M | $2.5M | 0.1% |
| 50 | QNCXQUINCE THERAPEUTICS INC | 5,498 | $100,009 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.